… Aberrant staining for p53 was defined as either strong diffuse nuclear staining in >75% of …
In addition, only 3 of these 5 mutations are found in the exon 3 region of CTNNB1, considered …

… Efforts to predict the clinical outcomes of different in-frame deletions based on systematic …
bulk delivery of any DNA or RNA payload to either normal or dystrophic muscle. Most cell types …

… TNNC1-positive probands had younger ages of diagnosis and poorer clinical outcomes.
Mapping of TNN variants identified locations in TNNT2 and TNNI3 associated with heightened …

… UM clinical samples processed either as fresh-frozen, formalin-fixed paraffin embedded (…
D630N on exon 20 [18]. The mutation identified in our study occurred in exon 18 and is the first …

… Ib/II clinical trial as a monotherapy and in combination with either TNO155 or spartalizumab
(… JUNIPER clinical trials against erlotinib in patients with KRAS mutant (exon 12 or exon 13) …

Endometrioid ovarian carcinoma (EnOC) demonstrates substantial clinical and molecular
heterogeneity. Here, we report whole exome sequencing of 112 EnOC cases following …

… The most common adverse events that were reported in at least 15% of the patients in either
… treatments, which do not improve clinical outcomes as compared with chemotherapy alone …

… oncogene-addicted NSCLC with either a BRAF or MET exon 14 skipping mutation might …
TT, with 3/4 achieving a clinical benefit. As for the MET exon 14 skipping mutation patients, 6/36 …

… Furthermore, we followed clinical outcomes of select patients … patients with tumors harboring
either exon 19 deletion, L858R or … T790 M was diagnosed either in the tumor specimen or in …

… data obtained from a subgroup of patients (n = 11) demonstrated either improvement or no
… of exon 7 of the SMN1 gene encoding the survival motor neuron (SMN) protein. The clinical …